Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene −572C>G polymorphism in subjects with and without hypertension

被引:0
作者
L Y F Wong
R Y H Leung
K L Ong
B M Y Cheung
机构
[1] The University of Hong Kong,Department of Medicine
来源
Journal of Human Hypertension | 2007年 / 21卷
关键词
interleukin-6; polymorphism; fibrinogen; C-reactive protein;
D O I
暂无
中图分类号
学科分类号
摘要
Hypertension is an important risk factor for cardiovascular diseases. There is increasing evidence suggesting that inflammation is involved in the development of hypertension. Interleukin-6 (IL-6) is an important mediator of inflammatory response and the major regulator of hepatic production of acute phase proteins, such as fibrinogen and C-reactive protein (CRP), which have been associated with hypertension and cardiovascular diseases. Therefore, we studied the association of single nucleotide polymorphism (SNP) in the IL-6 gene (IL6) promoter with plasma levels of fibrinogen, CRP and hypertension. Five hundred and two Hong Kong Chinese subjects (282 normotensives and 220 hypertensives) were recruited. IL-6 gene promoter was examined for polymorphism and the study subjects were genotyped for any SNP identified. The IL6 −572C>G polymorphism (rs1800796) was found with a frequency of 0.23 for the minor G allele. Subjects with the −572G allele had significantly higher plasma fibrinogen (3.06±0.57 vs 2.83±0.60, P=0.002) and CRP (interquartile range 0.33–1.56 vs 0.12–0.93, P=0.003) levels than those without. The −572C>G polymorphism was found to be an independent predictor of fibrinogen and CRP levels after adjusting for confounding factors. Plasma concentrations of fibrinogen and CRP correlated with systolic blood pressure. However, the −572C/G genotype frequencies did not differ between hypertensive and normotensive subjects, and there was no association between −572C>G polymorphism and blood pressure. Our results provide evidence that there is a clear genetic influence of IL6 −572C>G polymorphism on plasma levels of fibrinogen and CRP, but this polymorphism does not lead to elevated blood pressure.
引用
收藏
页码:875 / 882
页数:7
相关论文
共 213 条
[1]  
Hansson GK(2005)Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 1685-1695
[2]  
Li JJ(2005)Inflammation may be a bridge connecting hypertension and atherosclerosis Med Hypotheses 64 925-929
[3]  
Chen JL(2004)Interleukin-6 and cardiovascular diseases Jpn Heart J 45 183-193
[4]  
Kanda T(2001)Interleukin 6 and haemostasis Br J Haematol 115 3-12
[5]  
Takahashi T(2003)IL-6 is produced by splenocytes derived from CMV-infected mice in response to CMV antigens, and induces MCP-1 production by endothelial cells: a new mechanistic paradigm for infection-induced atherogenesis Atherosclerosis 170 223-228
[6]  
Kerr R(1998)IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses J Clin Invest 101 311-320
[7]  
Stirling D(1989)Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes FEBS Lett 242 237-239
[8]  
Ludlam CA(2003)Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives Hypertens Res 26 723-729
[9]  
Rott D(2003)Fibrin(ogen) in cardiovascular disease: an update Thromb Haemost 89 601-609
[10]  
Zhu J(1999)Inflammation markers and coronary heart disease Curr Opin Lipidol 10 435-441